CRNX News and Press, Crinetics Pharmaceuticals Inc. From 06/11/20

28 patients have completed the open-label Edge trial measuring IGF-1 levels after 13 weeks of treatment when patients with acromegaly were switched to once daily oral paltusotine from commercially available depot injections of the peptide somatostatin receptor ligands (SRLs) Recruitme...

SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the...

Crinetics Pharmaceuticals (NASDAQ: CRNX ): Q1 GAAP EPS of -$0.71 misses by $0.08 . More news on: Crinetics Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Reported positive interim results for the ACROBAT Edge Phase 2 trial of oral paltusotine in the treatment of acromegaly Completed successful public offering raising net proceeds of $107.9 million SAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: C...

Crinetics Pharmaceuticals (NASDAQ: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, has closed an underwritten public offering of 8,222,500 shares of its co...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most i...

SAN DIEGO, April 17, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today t...

Crinetics Pharmaceuticals ( CRNX +0.7% ) has priced its public offering of 7.15M common shares at $14.00/share, for expected gross proceeds of $100.1M. More news on: Crinetics Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...

SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today t...

Gainers: UAL   +7.5% .   PVAC   +6.7% . AAL   +6.7% . GME   +6.6%.  FHN   +5.9% . More news on: United Airlines Holdings, Inc., Penn Virginia Corporation, American Airlines Group Inc., Stocks on the move, , Read more ...